<DOC>
	<DOCNO>NCT01973491</DOCNO>
	<brief_summary>This multi-center , open-label , single arm , baseline-controlled Phase 2a trial evaluate clinical biological effect ATX-MS-1467 subject relapse multiple sclerosis ( MS ) ass maintenance effect .</brief_summary>
	<brief_title>ATX-MS-1467 Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Male female outpatient age 18 65 year age inclusive time informed consent Willing able provide write informed consent comply requirement protocol assessments/procedures Relapsing MS ( relapsingremitting multiple sclerosis [ RRMS ] , secondary progressive multiple sclerosis [ SPMS ] , define revise McDonald criterion [ 2010 ] ) ( 11 ) Clinical evidence recent MS activity radiological activity gadolinium ( Gd ) enhance magnetic resonance imaging ( MRI ) define define protocol Expanded disability status scale ( EDSS ) score 05.5 Human leukocyte antigenbeta chain ( HLADRB ) 1*15 positive Neurological stability 30 day prior Visit 5 ( Study Day 1 ) Prior vaccination tuberculosis ( TB ) If female , unless postmenopausal ( least 2 year ) surgically sterilize , must willing use two highly effective method contraception throughout entire duration trial 90 day follow last dose ATXMS1467 If male , must willing use two highly effective method contraception throughout entire duration trial 90 day follow last dose ATXMS1467 Primary progressive MS Inability comply MRI scanning , include contraindication MRI know allergy gadolinium contrast dye , claustrophobia , presence pacemaker , cochlear implant , ferromagnetic device clip , intracranial vascular clip , insulin pump , nerve stimulators Previous treatment betainterferon , plasma exchange , intravenous gamma globulin within 8 week prior study Day 1 ( Visit 5 ) , steroid ( administer via oral and/or parenteral route ) adrenocorticotropic hormone within 30 day prior Visit 2 MRI scan , glatiramer acetate , cytotoxic agent Prior exposure dimethyl fumurate ( BG12 ) dirucotide , diseaserelated T cell vaccine peptidetolerizing agent treatment MS , include ATXMS1467 Use investigational drug experimental procedure MS ( include cytokine anticytokine therapy ) within 30 day prior screen ( Visit 1 ) Inadequate liver function define protocol . Lymphocyte count le ( &lt; ) 500 per micro liter ( /mcL ) neutrophil count &lt; 1500 mcL screen pretreatment visit ( Visits 24 ) Major medical illness define protocol Known history active chronic infectious disease disease compromise immune function Any renal condition would preclude administration gadolinium History malignancy , include solid tumor hematological malignancy , exclude basal cell situ squamous cell carcinoma skin excise resolve , situ cervical cancer prostatic cancer normal prostatic specific antigen Clinical evidence severe uncontrolled depression , active suicidal ideation suicide attempt Any significant medical psychiatric condition , opinion Investigator , would preclude participation trial impair ability give inform consent Major surgery 4 week prior screen ( Visit 1 ) Known hypersensitivity trial medication diluent Participation another clinical trial within 30 day prior screen ( Visit 1 ) Pregnancy , lactation positive pregnancy test screening ( urine dipstick ) Visit 4 ( serum betahuman chorionic gonadotrophin [ betahCG ] ) , intention become pregnant breastfeed course trial Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ATX-MS-1467 ( MSC2358825A )</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Magnetic resonance imaging ( MRI )</keyword>
	<keyword>M2736</keyword>
</DOC>